BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer
August 16, 2017 at 07:17 AM EDT
* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:
